External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ELCC 2026

-
Coming soon
11:00 AM
Duration 60mins Copenhagen, Denmark
IMforte: Subsequent Treatment Following First-Line Maintenance With Lurbinectedin + Atezolizumab or Atezolizumab in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Yuanbin Chen, Luis Paz-Ares, Hossein Borghaei, Martin Reck, Roy S Herbst, Solange Peters, Grzegorz Czyżewicz, Reyes Bernabé Caro, Melissa L Johnson, Nuri Karadurmuş, Christian Grohé, Sofia Baka, Tibor Csőszi, Xiaoyan Wang, Kamalnayan Bhatt, Stefan Faderl, Vilma Graupner, Vaikunth Cuchelkar, Ya-Chen Lin, Stephen V Liu

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 61mins Copenhagen, Denmark
Neoadjuvant divarasib shows manageable safety and promising activity in patients with resectable, early-stage, KRAS G12C+ NSCLC: First results from the NAUTIKA1 KRAS G12C+ cohort
Jamie Chaft, Cummings A, Mohindra N, Negrao M, He K, Kim S-Y, Saltos A, Patil T, Shum E, Lammers P, Schulze K, Zhu Q, Schutzman J, Brandao E, Ngiam C, Bara I, Lee J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Copenhagen, Denmark
7-Year survival in patients with extended-stage small cell lung cancer (ES-SCLC) treated with atezolizumab in the IMpower133 and IMbrella A extension study, including brain and liver metastases by SCLC molecular subtype
Martin Reck, Rafal Dziadziuszko, Shunichi Sugawara, Steven Kao, Maximilian Hochmair, Marie-Kathrin Breyer, Gilberto de Castro Junior, Reyes Bernabé Caro, Se Hyun Kim, Dariusz Kowalski, Zoran Andric, Huafei Li, Yu Deng, Barzin Y. Nabet, Minu K. Srivastava, Marcela Oancea, Stephen V. Liu

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar